Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL

Study Status

Open to Enrollment

Study Description

Researchers have begun to understand how reversible changes in expression of genes contribute to the development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed "epigenetics" since they do not involve mutations in genes themselves.

In this trial, we are studying a combination of 2 drugs that may work by reversing epigenetic changes in patients with diffuse large B-cell lymphoma (DLBCL) that has not responded well to chemotherapy.

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Relapsed or Refractory Diffuse Large B-Cell Lymphoma


Weill Cornell Medical College

Key Eligibility

  • Men and women age 18 and older
  • Diffuse Large B-Cell Lymphoma (DLBCL) relapsed after prior systemic therapy or resistant to prior systemic therapy
  • Have relapsed following or ineligible for autologous stem cell transplantation
  • No limit to number of prior therapies
  • More detailed eligibility discussed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page